Anisa Mburu

Anisa Mburu

Auto-generated profile, based on publicly available information

Anisa Mburu

Aga Khan Hospital Mombasa, Department of Gynecologic Oncology, Mombasa, Kenya

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2023 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
NANúria Agustí
Núria Agustí
GBGiulio Bonaldo
Giulio Bonaldo
RKRyan M Kahn
Ryan M Kahn
ARAndrea Rosati
Andrea Rosati
DNDania Nachira
Dania Nachira
PRPedro T Ramirez
Pedro T Ramirez
Epithelial ovarian cancer most commonly presents at advanced stages, and prognosis is influenced by residual disease following cytoreduction. The significance of cardiophrenic lymph node resection at the time of cytoreductive surgery in advanced ovarian cancer remains a topic of debate. Enlarged cardiophrenic lymph nodes are detected through high-resolution imaging; however, the optimal imaging technique in determining feasibility of node resection remains uncertain. Similarly, the impact of excision of cardiophrenic lymph nodes on progression-free and overall survival remains elusive. The indications for resection of cardiophrenic lymph nodes are not addressed in standard ovarian cancer guidelines. Patients with cardiophrenic lymph nodes exceeding 1 cm in size may be considered for resection if complete intra-abdominal cytoreduction is feasible to no gross residual. The surgical approach might be either by open access or by video-assisted thoracoscopic surgery (minimally invasive approach), and major complications following cardiophrenic lymph nodes resection are low. Pathological cardiophrenic lymph nodes are associated with a poorer overall prognosis and can serve as a prognostic parameter; however, the therapeutic benefit of cardiophrenic lymph nodes resection remains inconclusive.

1 August 2024 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
AJAarthi S Jayraj
Aarthi S Jayraj
SASalamatu Abdul-Aziz
Salamatu Abdul-Aziz
AMAnisa Mburu
Anisa Mburu
AUAvinash Upadhyay
Avinash Upadhyay
NSNilanchali Singh
Nilanchali Singh
PGPrafull Ghatage
Prafull Ghatage
Background and Objective: Serous endometrial cancers (ECs) are an aggressive histotype of ECs which are disproportionately responsible for 40% of cancer-specific mortality rates despite constituting only 5–10% of all uterine cancers in incidence. In recent times, it has become increasingly evident that about 20–40% of uterine serous cancers (USCs) have molecular alterations in ERBB2 pathway with human epidermal growth factor receptor 2 (HER2/neu) amplification or overexpression. We summarise the evidence on genetic and molecular alterations in HER2/neu pathway in USC with a focus on testing criteria, targeting agents and resistance mechanisms. Methods: We conducted a database search of PubMed/Medline up to 28th February 2023 for articles published in the English language using pre-defined search terms. One hundred and seventy-one relevant articles were subsequently reviewed for eligibility and inclusion in the review. Key Content and Findings: The Cancer Genome Atlas (TCGA) classification is a significant development in the molecular profiling of ECs with a positive impact on the treatment of these tumors including USCs. Testing criteria for HER2/neu in USC with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) has evolved in more than a decade with progress made towards EC specific testing guidelines. The findings of a recent phase III study have led to the development of practice changing guidelines towards improving patient outcomes. Conclusions: Molecular aberration in the HER2/neu pathway contributes to the aggressive behaviour of USC. Considering the clinical benefit conferred by HER2/neu targeted therapy, HER2/neu testing is recommended for all cases of serous EC in advanced and recurrent settings. Trastuzumab in combination with platinum and taxanes based chemotherapy is the recommended treatment option for patients with advanced or recurrent serous cancers who test positive to HER2/neu. Clinical trials on targeted therapy are ongoing and future research should focus on selection of patients who will derive the most benefit from such therapy.

6 January 2026 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PFParisa N. Fallah
Parisa N. Fallah
AMAnisa Mburu
Anisa Mburu
RRRicardina Rangeiro
Ricardina Rangeiro
SKSaujanya Karmacharya
Saujanya Karmacharya
MKMukatimui Kalima-Munalula
Mukatimui Kalima-Munalula
KSKathleen M. Schmeler
Kathleen M. Schmeler

23 June 2024 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
KFKeiichi Fujiwara
Keiichi Fujiwara
SCStephen Robert Connor
Stephen Robert Connor
NFNoriko Fujiwara
Noriko Fujiwara
RORaimundo C. Oliveira
Raimundo C. Oliveira
AMAnisa Mburu
Anisa Mburu
MPMichael Loran Pearl
Michael Loran Pearl
At the International Gynecologic Cancer Society (IGCS) Global Meeting in 2023 held in Seoul, South Korea, we held a Presidential Plenary Session focusing on palliative care (https://www.youtube.com/watch?v=TBDIoQ50xgI). We hereby reaffirm the significance of this session, express the Palliative Care Declaration made by the IGCS, and describe our action plan for the future.

10 March 2022 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
AMAnisa W. Mburu
Anisa W. Mburu
PIPeter M. Itsura
Peter M. Itsura
EOElkanah O. Orang'O
Elkanah O. Orang'O
PTPhilliph K. Tonui
Philliph K. Tonui
EOElly B. Odongo
Elly B. Odongo
BRBarry P. Rosen
Barry P. Rosen
The main pediatric (0–18 years) gynecologic cancers include stromal carcinomas (juvenile granulosa cell tumors and Sertoli-Leydig cell tumors), genital rhabdomyosarcomas and ovarian germ cell. Outcomes depend on time of diagnosis, stage, tumor type and treatment which can have long-term effects on the reproductive career of these patients. This study seeks to analyze the trends in clinical-pathologic presentation, treatment and outcomes in the cases seen at our facility. This is the first paper identifying these cancers published from sub-Saharan Africa. Retrospective review of clinico-pathologic profiles and treatment outcomes of pediatric gynecologic oncology patients managed at MTRH between 2010 and 2020. Data was abstracted from gynecologic oncology database and medical charts. Records of 40 patients were analyzed. Most, (92.5%, 37/40) of the patients were between 10 and 18 years. Ovarian germ cell tumors were the leading histological diagnosis in 72.5% (29/40) of the patients; with dysgerminomas being the commonest subtype seen in 12 of the 37 patients (32.4%). The patients received platinum-based chemotherapy in 70% of cases (28/40). There were 14 deaths among the 40 patients (35%) Surgery remains the main stay of treatment and fertility-sparing surgery with or without adjuvant platinum-based chemotherapy are the standard of care with excellent prognosis following early detection and treatment initiation. LMICs face several challenges in access to quality care and that affects survival of these patients. Due to its commonality, ovarian germ cell cancers warrant a high index of suspicion amongst primary care providers attending to adnexal masses in this age group.

4 July 2022 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
AMAnisa Mburu
Anisa Mburu
PTPhilliph Tonui
Philliph Tonui
KKKibet Keitany
Kibet Keitany
RORaymond J Osborne
Raymond J Osborne